Gapping up
In reaction to earnings/guidance:
- CRNC +7.6%, AZUL +6%, TSN +4%, VOD +3.2%, PANW +2.8%, INBX +1%
M&A news:
- FBM +26.9% (Foundation Building Materials to be acquired for $19.25 per share in cash)
- BBVA +18.4% (PNC agrees to purchase BBVA USA Bancshares for $11.6 bln)
- TCO +8.3% (Taubman Centers and Simon Property Group (SPG) modify merger price to $43.00 per share in cash)
- SPG +6.6% (Taubman Centers and Simon Property Group (SPG) modify merger price to $43.00 per share in cash)
- PNC +4.5% (PNC agrees to purchase BBVA USA Bancshares for $11.6 bln)
- UBER +3% (co is in talks to sell ATG self-driving unit, according to TechCrunch)
Other news:
- VJET +20.9% (receives follow-up order for three additional units of its new high-speed 3D printer)
- MRNA +17.4% (COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study; vaccine efficacy of 94.5%)
- ABUS +14.3% (presents Phase 1a/1b clinical trial results for AB-729 in Chronic Hepatitis B)
- INO +12.3% (received clearance from the U.S. Food & Drug Administration (FDA) to proceed with the Phase 2 segment of its planned Phase 2/3 clinical trial for INO-4800, its COVID-19 vaccine candidate)
- OBSV +11.1% (reports topline results of the PROLONG proof-of-concept trial of Ebopiprant)
- BYSI +9.8% (announces positive topline results from its PROTECTIVE-2 Phase 3 registrational trial of plinabulin in combination with pegfilgrastim for prevention of chemotherapy-induced neutropenia)
- PLTR +6% (Soros Fund (George Soros) and Third Point (Dan Loeb) discloses new portfolio positions in 13F filing)
- LQDA +4.3% (Liquidia Technologies approve the previously announced RareGen merger agreement; expected to close on or about November 18, 2020)
- FLR +4% (announces that the company has reached an agreement with Sargent & Lundy to collaborate with joint marketing and design services for the execution of new NuScale Power small modular nuclear reactor plants in North America)
- RIDE +2.8% (releases business updates; remains on track to begin production of the lordstown endurance in September 2021)
- DVAX +2.4% (Dynavax and Biological E. Limited initiated a Phase I/II clinical trial of its COVID-19 subunit vaccine candidate in India following approval from the Drugs Controller General of India)
- BHC +2.3% (announces investigational in vitro data indicating complete inactivation of SARS-CoV-2 with LUMIFY and BESIVANCE eye drops preserved with benzalkonium chloride)
- AOSL +1.8% (Alpha and Omega Semi announces that COO and co-founder Dr. Yueh-se Ho will retire; Stephen Chang promoted to President)
- MRK +1.6% (announces that the FDA has approved KEYTRUDA for triple-negative breast cancer)
- JNJ +1.5% (Johnson & Johnson and U.S. Department of Health & Human Services expand agreement to support next phase of COVID-19 vaccine candidate research and development)
- CTVA +1.4% (Starboard Value (Jeffrey Smith) discloses new portfolio positions in 13F filing)